BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32348628)

  • 41. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor.
    Zhang C; Chou CJ
    Org Lett; 2016 Nov; 18(21):5512-5515. PubMed ID: 27759399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
    Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
    J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
    Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
    Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
    Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
    Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
    Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
    Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety.
    Bui HTB; Nguyen PH; Pham QM; Tran HP; Tran Q; Jung H; Hong QV; Nguyen QC; Nguyen QP; Le HT; Yang SG
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.
    Soumyanarayanan U; Ramanujulu PM; Mustafa N; Haider S; Fang Nee AH; Tong JX; Tan KSW; Chng WJ; Dymock BW
    Eur J Med Chem; 2019 Dec; 184():111755. PubMed ID: 31627059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent innovative advances in the discovery of selective HDAC6 inhibitors.
    T Tavares M; Shen S
    Future Med Chem; 2021 Jun; 13(12):1017-1019. PubMed ID: 33906379
    [No Abstract]   [Full Text] [Related]  

  • 55. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
    Zhang S; Huang W; Li X; Yang Z; Feng B
    Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
    Singh RK; Suzuki T; Mandal T; Balsubramanian N; Haldar M; Mueller DJ; Strode JA; Cook G; Mallik S; Srivastava DK
    Biochemistry; 2014 Dec; 53(48):7445-58. PubMed ID: 25407689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.
    Ortore G; Di Colo F; Martinelli A
    J Chem Inf Model; 2009 Dec; 49(12):2774-85. PubMed ID: 19947584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.